Which antidepressant is safe for a patient who previously experienced acute angle‑closure glaucoma while taking duloxetine (Cymbalta)?

Antidepressant Selection After Duloxetine-Induced Acute Angle Closure

For a patient who experienced acute angle-closure glaucoma with duloxetine, bupropion is the safest antidepressant choice, as it lacks the serotonergic and anticholinergic properties that precipitate angle closure. 1

Understanding the Risk

Duloxetine (Cymbalta) is contraindicated in uncontrolled narrow-angle glaucoma and should be used cautiously even in controlled narrow-angle glaucoma due to its mydriatic effects 2. Your patient has now demonstrated anatomic predisposition to angle closure, making this a critical safety concern.

Mechanism of Antidepressant-Induced Angle Closure

Antidepressants trigger acute angle-closure through two primary mechanisms 3:

• Pupillary block mechanism: Mydriasis (pupil dilation) from adrenergic effects and anticholinergic activity causes iris bunching in anatomically narrow angles
• Timing: Most events occur within days to weeks of starting treatment or dose escalation 4, 5

The case literature documents duloxetine causing bilateral acute angle closure within 2 days of initiation 5, and recent meta-analysis confirms antidepressants as a class increase acute angle-closure risk (OR 1.62,95% CI 1.16-2.26) 4.

Safe Antidepressant Options

First Choice: Bupropion

• Mechanism: Norepinephrine-dopamine reuptake inhibitor with NO serotonergic activity
• Angle-closure risk: Minimal—lacks the serotonergic and anticholinergic properties that cause mydriasis
• Evidence: Not implicated in angle-closure case reports or epidemiologic studies 1, 6, 7

Alternative: Mirtazapine

• Mechanism: Alpha-2 antagonist with unique receptor profile
• Angle-closure risk: Lower than SSRIs/SNRIs, though theoretical risk exists
• Consideration: May cause sedation and weight gain

Antidepressants to AVOID

All serotonergic antidepressants carry increased risk in your patient:

• SNRIs (venlafaxine, desvenlafaxine, levomilnacicran): Same class as duloxetine with similar mydriatic effects 5, 3
• SSRIs (fluoxetine, paroxetine, sertraline, citalopram, escitalopram, fluvoxamine): Multiple case reports of acute angle closure 6, 4, 5
• Tricyclic antidepressants: Strong anticholinergic effects cause significant mydriasis 8, 3

While recent meta-analysis suggests SSRIs may not increase open-angle glaucoma risk and may even lower IOP 6, this finding is irrelevant to your patient—they have angle-closure disease, not open-angle glaucoma. The pupillary dilation from SSRIs remains dangerous in narrow angles.

Essential Ophthalmologic Management

Before starting ANY antidepressant, ensure:

1. Bilateral laser peripheral iridotomy (LPI) has been performed 9

   • The fellow eye has ~50% risk of acute angle closure within 5 years without prophylactic treatment 9
   • LPI should be performed "as soon as possible" after the acute event 9

2. Gonioscopy confirmation that angles are now adequately open post-LPI 9

3. Consider lens extraction if significant cataract present or persistent narrow angles despite LPI 9

   • The EAGLE trial demonstrated superior IOP control and quality of life with lens extraction versus LPI alone in angle-closure disease 9

Critical Counseling Points

Warn your patient about:

• Symptoms of acute angle closure: Severe eye pain, headache, blurred vision, halos around lights, nausea/vomiting 9
• Medication triggers: Over-the-counter decongestants, antihistamines, motion sickness drugs—all have anticholinergic properties 9, 3
• Immediate action: Seek emergency ophthalmologic care if symptoms develop

Clinical Algorithm

Patient with prior duloxetine-induced angle closure
    ↓
Confirm bilateral LPI performed → If not, refer urgently to ophthalmology
    ↓
Verify angles adequately open on gonioscopy
    ↓
SELECT ANTIDEPRESSANT:
    First line: Bupropion
    Alternative: Mirtazapine (if bupropion contraindicated/ineffective)
    ↓
AVOID: All SSRIs, SNRIs, TCAs
    ↓
Educate on angle-closure symptoms
    ↓
Coordinate with ophthalmology for monitoring

Common Pitfall

Do not assume LPI eliminates all risk. Even after successful iridotomy, some patients develop progressive synechial closure or have plateau iris syndrome requiring ongoing monitoring 9. Avoiding mydriatic medications remains prudent despite prophylactic treatment.

The American College of Physicians guideline emphasizes selecting antidepressants based on "adverse effect profiles" and patient-specific factors 1—your patient's documented angle-closure history makes bupropion the clear evidence-based choice to prevent potentially blinding recurrence.